Towards targeting of adaptive immune responses in rheumatoid arthritis

A. Musters

Towards targeting of adaptive immune responses in rheumatoid arthritis

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

The therapeutic options for rheumatoid arthritis (RA) have increased immensely in the past two decades and resulted in improvements in outcome and quality of life. Especially, the arrival of biological and targeted synthetic disease-modifying anti-rheumatic drugs, with therapeutic targets ranging from cytokines (e.g. tumor necrosis factor to CD20 on B-cells, has dramatically

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	de Vries, Niek, Supervisor Tas, Sander, Supervisor
Award date	29 Nov 2023
Print ISBNs	9789464832600
Publication status	Published - 2023

Access to Document

Cite this

@phdthesis{7176cacd41794b2db065da860f446401,

title = "Towards targeting of adaptive immune responses in rheumatoid arthritis",

abstract = "The therapeutic options for rheumatoid arthritis (RA) have increased immensely in the past two decades and resulted in improvements in outcome and quality of life. Especially, the arrival of biological and targeted synthetic disease-modifying anti-rheumatic drugs, with therapeutic targets ranging from cytokines (e.g. tumor necrosis factor to CD20 on B-cells, has dramatically",

author = "A. Musters",

year = "2023",

language = "English",

isbn = "9789464832600",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Towards targeting of adaptive immune responses in rheumatoid arthritis

AU - Musters, A.

PY - 2023

Y1 - 2023

N2 - The therapeutic options for rheumatoid arthritis (RA) have increased immensely in the past two decades and resulted in improvements in outcome and quality of life. Especially, the arrival of biological and targeted synthetic disease-modifying anti-rheumatic drugs, with therapeutic targets ranging from cytokines (e.g. tumor necrosis factor to CD20 on B-cells, has dramatically

AB - The therapeutic options for rheumatoid arthritis (RA) have increased immensely in the past two decades and resulted in improvements in outcome and quality of life. Especially, the arrival of biological and targeted synthetic disease-modifying anti-rheumatic drugs, with therapeutic targets ranging from cytokines (e.g. tumor necrosis factor to CD20 on B-cells, has dramatically

UR - https://pure.uva.nl/ws/files/145108320/Licentieovereenkomst_medeondertekend_.pdf

UR - https://pure.uva.nl/ws/files/145108322/Stellingen.pdf

M3 - Phd-Thesis - Research and graduation internal

SN - 9789464832600

ER -

Towards targeting of adaptive immune responses in rheumatoid arthritis

Abstract

Access to Document

Other files and links

Cite this